Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia

Atherosclerosis

Volumn 191, Issue 2, 2007, Pages 397-402

  Aslan, Mehmet ^a   Kosecik, Mustafa ^a   Horoz, Mehmet ^a   Selek, Sahbettin ^a   Celik, Hakim ^a   Erel, Ozcan ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Arylesterase; Atherosclerosis; Iron deficiency anemia; Lipid hydroperoxide; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; LIPID HYDROPEROXIDE; SODIUM CHLORIDE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

ADULT; ANEMIA, IRON-DEFICIENCY; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; HUMANS; LIPID PEROXIDATION; LIPID PEROXIDES; MIDDLE AGED; OXIDATIVE STRESS; SPECTROPHOTOMETRY;

EID: 33947098990     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.04.007     Document Type: Article

References (53)

1. DeMaeyer E., and Adiels Tegman M. The prevalence of anaemia in the world. World Health Stat Q 38 (1985) 302-316
2. Rockey D.C., and Cello J.P. Evaluation of the gastrointestinal tract in patients with iron deficiency anemia. N Engl J Med 329 (1993) 1691-1695
3. Lieberman E., Ryan K.J., Monson R.R., and Schoenbaum S.C. Association of maternal hematocrit with premature labor. Am J Obstet Gynecol 159 (1988) 107-114
4. Oski F.A., Honig A.S., Helu B., and Howanitz P. Effect of iron therapy on behavior performance in nonanemic, iron-deficient infants. Pediatrics 71 (1983) 877-880
5. Mackness B., Durrington P.N., and Mackness M.I. Human Serum. Paraoxonase. Gen Pharmacol 39 (2004) 59-66
6. Canales A., and Sanchez-Muniz F.J. Paraoxanase, something more than an enzyme?. Med Clin (Barc) 121 (2003) 537-548
7. Blatter M.C., James R.W., Messmer S., Barja F., and Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 211 (1993) 871-879
8. Kosaka T., Yamaguchi M., Motomura T., and Mizuno K. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin Chim Acta 359 (2005) 156-162
9. Mackness M.I., and Durrington P.N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 115 (1995) 243-253
10. Marenberg M.E., Risch N., Berkman L.F., Floderus B., and de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. New Engl J Med 330 (1994) 1041-1046
11. Ayub A., Mackness M.I., Arrol S., et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 19 (1999) 330-335
12. Mackness M.I., Harty D., Bhatnagar D., et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 86 (1991) 193-199
13. Paragh G., Seres I., Balogh Z., et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80 (1998) 166-170
14. Mackness M.I., Abbott C., Arrol S., and Durrington P.N. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 294 (1993) 829-834
15. Parthasarathy S., Barnett J., and Fong L.G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1044 (1990) 275-283
16. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet 344 (1994) 793-795
17. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase: inhibitition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995) 2882-2891
18. La Du B.N., Piko J.I., Eckerson H.W., Vincent-Viry M., and Siest G. An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism. Ann Biol Clin 44 (1986) 369-372
19. Brophy V.H., Jampsa R.L., Clendenning J.B., Mckinstry L.A., and Furlong C.E. Effects of 5 V regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68 (2001) 1428-1436
20. Suehiro T., Nakamura T., Inoue M., et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150 (2000) 295-298
21. Adkins S., Gan K.N., Mody M., and La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase: arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52 (1993) 598-608
22. Mackness M.I., Arrol S., Mackness B., and Durrington P.N. The allo enzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low-density lipoprotein against lipid-peroxidation. Lancet 349 (1997) 851-852
23. Mackness B., Mackness M.I., Arrol S., Turkie W., and Durrington P.N. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 112 (1997) 265-268
24. Aviram M. Does paraoxonase play role in susceptibility of cardiovascular disease?. Mol Med Today 5 (1999) 381-386
25. Eckerson H.W., Wyte M.C., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35 (1983) 1126-1138
26. Haagen L., and Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clim Biochem 30 (1992) 391-395
27. Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 300 (1999) 58-62
28. Halliwell B. Antioxidants in human health and disease. Annu Rev Nutr 16 (1996) 33-50
29. Ramachandran M., and Iyer G.Y. Erythrocyte membrane lipid peroxidation in iron deficiency anemia. Experientia 40 (1984) 173-174
30. Jansson L.T., Perkkio M.V., Willis W.T., Refino C.J., and Dallman P.R. Red cell superoxide dismutase is increased in iron deficiency anemia. Acta Haematol 74 (1985) 218-221
31. Macdougall L.G. Red cell metabolism in iron deficiency anemia. The relationship between glutathione peroxidase, catalase, serum vitamin E, and susceptibility of irondeficient red cells to oxidative hemolysis. J Pediatr 80 (1972) 775-782
32. Kurtoglu E., Ugur A., Baltaci A.K., and Undar L. Effect of iron supplementation on oxidative stress and antioxidant status in iron deficiency anemia. Biol Trace Elem Res 96 (2003) 117-123
33. Isler M., Delibas N., Guclu M., et al. Superoxide dismutase and glutathione peroxidase in erythrocytes of patients with iron deficiency anemia: effects of different treatment modalities. Croat Med J 43 (2002) 16-19
34. McCord J.M. The evolution of free radicals and oxidative stress. Am J Med 108 (2000) 652-659
35. Akins P.T., Glenn S., Nemeth P.M., and Derdeyn C.P. Carotid artery thrombus associated with severe iron deficiency anemia and thrombocytosis. Stroke 27 (1996) 1002-1005
36. Aoki N., and Sakai T. Cerebral sinus thrombosis in patients with severe iron deficiency anemia due to myoma ueri. Acta Neurochir (Wien) 97 (1989) 131-134
37. Shimamoto T. The 'emergency reaction' in thrombogenesis and atherogenesis. Am Heart J 66 (1963) 572-573
38. Hartfield D.S., Lowry N.J., Keene D.L., and Yager J.Y. Iron deficiency: a cause of stroke in i{dotless}nfants and children. Pediatr Neurol 16 (1997) 50-53
39. Witzum J.L., and Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88 (1991) 1785-1792
40. Esterbauer H., Wag G., and Puhl H. Lipid peroxidation and its role in atherosclerosis. Br Med Bull 49 (1993) 566-576
41. Mackness B., Hunt R., Durrington P.N., and Mackness M.I. Increased immunolocalization of paraoxonase, clusterin and apolipoproteins A-I in the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 17 (1997) 1233-1238
42. Seres I., Paragh G., Deschene E., Fulop Jr. T., and Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 39 (2004) 59-66
43. Hedrick C.C., Hassan K., Hough G.P., et al. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler Thromb Vasc Biol 2 (2000) 1946-1952
44. James R.W., Leview I., and Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101 (2000) 2252-2257
45. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
46. Shih D.M., Xia Y.R., Miller E., et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275 (2000) 17527-17535
47. Mackness M.I., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286 (1991) 152-154
48. Aviram M., Rosenblat M., Bisgaier C.L., et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101 (1998) 1581-1590
49. Miller N.E., La Ville A., and Crook D. Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature 314 (1985) 109-111
50. Suehiro T., Nakauchi Y., Yamamoto M., et al. Paraoxonase gene polymorphism in Japanese subjects with coronary artery disease. Int J Cardiol 57 (1996) 69-73
51. Ruiz J., Blanche H., James R.W., et al. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346 (1995) 869-872
52. Jarvik G.P., Hatsukami T.S., Carlson C., et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 23 (2003) 1465-1471
53. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 21 (2001) 1451-1457